NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Efficacy of Prazosin Versus Placebo Associated With Peg-interferon Alpha 2b and Ribavirin in Chronic Hepatitis C With Genotype 1 or 4 and Severe Fibrosis

NCT00148837

CompletedPhase 2

Sponsor: French National Agency for Research on AIDS and Viral Hepatitis

Conditions: Hepatitis C, Chronic, Fibrosis

Interventions: Peg-interferon alpha 2b + Ribavirin(drug), Prazosin (drug)

Countries: France

Viral hepatitis C prognosis is related to the presence of a fibrosis and to the risk of developing cirrhosis or hepatic cancer. The study will evaluate the efficacy of prazosin to make hepatic fibrosis regress, in patients with chronic hepatitis C and severe fibrosis.

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria:

* Chronic viral hepatitis C, genotype 1 or 4
* Fibrosis F3 or F3-F4, assessed by the scoring Metavir system
* Initial treatment against HCV

Exclusion Criteria:

* Psychiatric pathology
* Alcool consummation
* Pregnancy or plan of pregnancy
* Breastfeeding

Locations (1)

Pessac, France